Specialize in Nuclear Medicine and increase your prestige by helping to detect and treat different pathologies thanks to this Professional master’s degree" 

Nuclear Medicine is one of the health areas that is currently experiencing greatest advances. This specialty makes it possible to find and treat different pathologies that, by other means, would be imperceptible or would be detected late. Moreover, its efficiency and precision make it one of the most sought-after fields by the major medical services of the best clinics in the world. 

For that reason, going deeper into this subject can make the physicians a prestigious professional who enjoys great opportunities to advance their careers, in addition to updating their knowledge in a field in constant transformation. Thus, this

Professional master’s degree in Nuclear Medicine is the perfect educational program for all those who wish to deepen their knowledge in this area that will turn them into reputed doctors. 

Thus, this degree offers its students highly specialized contents with which they will be able to master issues such as single photon emission applied to Nuclear Medicine, Nuclear Medicine related to pediatrics, nuclear treatments of neuroendocrine tumors or the use of radioguided surgery.  

With this knowledge, physicians who complete the program will have become experts in this field and will have updated their skills so that they have mastered the latest techniques in this area. Thus, they will be able to progress professionally, being able to access the Nuclear Medicine services of the major clinics in the country. 

This program, moreover, is taught through an innovative 100% online teaching methodology that will allow doctors to combine their professional careers and personal lives with their studies, since it has been designed to adapt to the circumstances of each individual. In this way, the learning process is facilitated while maintaining a high educational level and guaranteeing that students will be true specialists in Nuclear Medicine when they complete this Professional master’s degree.

Nuclear Medicine offers innovative techniques to treat complex pathologies. Enroll now and offer the best services to your patients with this innovative degree" 

This Professional master’s degree in Nuclear Medicine contains the most complete and up-to-date scientific program on the market. Its most notable features are:

• The development of case studies presented by experts in Nuclear Medicine 
• The graphic, schematic, and eminently practical contents with which they are created, provide scientific and practical information on the disciplines that are essential for professional practice
• Practical exercises where self-assessment can be used to improve learning 
• Its special emphasis on innovative methodologies  
• Theoretical lessons, questions to the expert, debate forums on controversial topics, and individual reflection assignments 
• Content that is accessible from any fixed or portable device with an Internet connection 

Specialization is the key: with this degree you will enhance your reputation and progress in the exciting field of Nuclear Medicine" 

The program’s teaching staff includes professionals from the sector who contribute their work experience to this training program, as well as renowned specialists from leading societies and prestigious universities.  

The multimedia content, developed with the latest educational technology, will provide the professional with situated and contextual learning, i.e., a simulated environment that will provide immersive training programmed to train in real situations.  

This program is designed around Problem-Based Learning, whereby the professional must try to solve the different professional practice situations that arise during the academic year. This will be done with the help of an innovative system of interactive videos made by renowned experts in the field of Nuclear Medicine with extensive teaching experience.

Update your knowledge in Nuclear Medicine and become a prestigious specialist thanks to this Professional master’s degree"

Nuclear Medicine services are booming. Specialize and achieve all your professional goals"

The contents of this Professional master’s degree in Nuclear Medicine have been designed by the best experts in the field, and have been designed to offer students the latest techniques and treatments in this exciting field that can save many lives. Thus, at the end of this program, students will have become great specialists in Nuclear Medicine thanks to the knowledge they will have learned throughout its development. 

The most innovative and specialized contents in Nuclear Medicine can be found in this Professional master’s degree"

Module 1. Management

1.1. Strategic Planning  

1.1.1. Benefits  
1.1.2. Vision, Mission and Values of the Health Institution and the Nuclear Medicine Unit  
1.1.3. Models: SWOT Analysis  

1.2. Organization and Management  

1.2.1. Organizational and Functional Structure  
1.2.2. Technical Equipment  
1.2.3. Human Resources  

1.3. IT Systems  

1.3.1. Indicators and Indexes  

1.4. Knowledge Management  
1.5. Quality Program 

1.5.1. ISO Standards  
1.5.2. Clinical Audits  
1.5.3. Objectives of Clinical Audits  
1.5.4. The Audit Cycle  
1.5.5. Evidence-Based Medicine  
1.5.6. Elements of Quality: Structure, Process and Results  

1.6. Economic Assessment of Nuclear Medicine Processes  
1.7. Adequacy of Imaging Tests  

1.7.1. What Should Be Done?  
1.7.2. What Not to Do?  

1.8. Risk Management 

1.8.1. Levels of Responsibility 
1.8.2. Patient Security  

1.9. Nuclear Medicine Teleworking 

1.9.1. Technical Requirements  

Module 2. Radiomics 

2.1. Artificial Intelligence, Machine Learning, Deep Learning  
2.2. Radiomics Today  
2.3. Imaging Biomarkers  
2.4. Multidimensionality in Imaging  
2.5. Applications: Diagnosis, Prognosis and Prediction of Response  
2.6. Evidence Levels  
2.7. Combination with Other "omics": Radiogenomics 

Module 3. Single Photon Emission Nuclear Medicine: “pearls and pitfalls” 

3.1. Pneumology 

3.1.1. Perfusion/Ventilation 
3.1.2. Pulmonary Thromboembolism 
3.1.3. Pulmonary Hypertension 
3.1.4. Lung Transplant 
3.1.5. Pleuroperitoneal Fistula: Cirrhotic Patient, Peritoneal Dialysis 

3.2. Cardiology 

3.2.1. Perfusion: Ischemic Heart Disease, Cellular Viability, Contribution  
3.2.2. GATED, Myocarditis 
3.2.3. Shunt: Left-Right, Right-Left 
3.2.4. Ventricular Function: Ischemic Cardiopathy, Cardiotoxicity 
3.2.5. Cardiac Innervation: Cardiac Pathology, Neurological Pathology 

3.3. Vascular and Lymphatic System 

3.3.1. Peripheral Endothelial Function 
3.3.2. Lower Limb Perfusion 
3.3.3. Lymphogrammagraphy 

3.4. Osteoarticular 

3.4.1. Primary Benign and Malignant Tumor Pathology: Planar Imaging 
3.4.2. Hybrid Image Contribution 
3.4.3. Bone Metastasis: Contributions of SPECT and SPECT/CT, Usefulness in Diagnosis and Monitoring 
3.4.4. Benign Pathology: Metabolic Disease, Sports Pathology 

3.5. Nephrourology 

3.5.1. Assessment of Renal Malformations 
3.5.2. Obstructive Pathology: Hydronephrosis in Pediatric Age: Diagnosis and Monitoring, Adult Hydronephrosis, Urinary Diversion Study 
3.5.3. Pyelonephritis: Initial Diagnosis, Evolution 
3.5.4. Renal Transplantation: Rejection, Tubular Necrosis, Nephrotoxicity, Urinary Leakage 
3.5.5. Vasculorenal Hypertension: Diagnosis and Monitoring 
3.5.6. Glomerular Filtration and Effective Renal Plasma Flow 
3.5.7. Cystogammagraphy: Direct and Indirect in the Diagnosis and Monitoring of Vesicoureteral Reflux 

3.6. Gastroenterology 

3.6.1. Salivary Glands: Autoimmune Pathology, Post-radiation Damage, Salivary Gland Tumors 
3.6.2. Digestive Transit: Esophageal Transit, Gastroesophageal Reflux, Pulmonary Aspiration, Gastric Emptying 
3.6.3. Gastrointestinal Bleeding: Study with Labeled Red Blood Cells, Study with Radiocolloids 
3.6.4. Hepatobiliary Pathology: Aliasic Cholecystitis, Hepatic Functional Reserve Assessment, Hepatic Transplantation (Rejection, Biliary Leakage), Biliary Tract Atresia 
3.6.5. Bile Acid Malabsorption  
3.6.6. Inflammatory Bowel Disease: Diagnosis, Monitoring and Complications  
3.6.7. Hepatic Space-Occupying Lesion: Hepatic Hemangioma, Focal Nodular Hyperplasia vs. Adenoma 
3.6.8. Cell Labeling: Method and Indications 
3.6.9. Red Blood Cells: In Vivo, In Vitro, In Vivitro 
3.6.10. Leukocytes 

3.7. Splenic Pathology 

3.7.1. Hepatic Space-Occupying Lesions: Hemangioma, Hamartoma  
3.7.2. Splenosis: Study with Denatured Labeled Red Cells 
3.7.3. Cell Hijacking 

3.8. Endocrinology  

3.8.1. Thyroid: Hyperfunctioning Thyroid ( Autoimmune, Thyroiditis), Thyroid Nodule, Differentiated Thyroid Carcinoma 
3.8.2. Parathyroid: Hyperfunctioning Gland Location  
3.8.3. Adrenal Glands: Adrenal Cortex Pathology (Hypercortisolism, Hyperaldosteronism), Adrenal Medulla Pathology (Hyperplasia, Pheochromocytoma), Adrenal Incidentaloma 

3.9. Neurology SPECT vs. PET: 

3.9.1. Cognitive Impairment: Characteristic Patterns and Differential Diagnosis  
3.9.2. Movement Disorders: Parkinson's Disease, Parkinson Plus and Differential Diagnosis  
3.9.3. Epilepsy: Preoperative Assessment, Acquisition Protocols  

3.10. Oncology: Tumor Viability, Radionecrosis vs. Progression 

3.10.1. Brain Death 
3.10.2. Cerebrospinal Fluid (CSF)-Cysternogammography Kinetics: Hydrocephalus, CSF Leakage 

Module 4. Infection/Inflammation: Gammagraphic Studies and PET Tracers 

4.1. Osteoarticular 

4.1.1. Osteomyelitis: Previously Healthy Bone, Diabetic Patient, Spine Surgery 
4.1.2. Prosthesis: Septic vs. Aseptic Mobilization 

4.2. Cardiac  

4.2.1. Endocarditis: Native Valve, Prosthetic Valve 
4.2.2. Myocarditis: Infectious vs. Inflammatory 
4.2.3. Intracardiac Devices 

4.3. Vascular 

4.3.1. Inflammatory Vasculitis 
4.3.2. Prosthetic Graft Infection 

4.4. Encephalitis: PET-FDG Study 

4.4.1. Paraneoplastic 
4.4.2. Infectious: Patterns and Differential Diagnosis 

4.5. Fever of Unknown Origin 

4.5.1. Immunosuppressed Patients 
4.5.2. Postoperative Fever and Recurrent Sepsis 

4.6. Systemic Disease 

4.6.1. Sarcoidosis: Diagnosis, Extent and Response to Treatment  
4.6.2. IgG4-related Disease 

4.7. Other Locations 

4.7.1. Hepatorenal Polycystic Kidney Disease: Localization of the Infectious Focus 
4.7.2. Hepatobiliary: Post-surgical Patient 

4.8. Covid-19 

4.8.1. Nuclear Medicine Studies in Acute Phase: Pulmonary Inflammation, Pulmonary Thromboembolism, Oncology Patient and Covid-19 
4.8.2. Utility of Nuclear Medicine in Post-covid Pathology: Pulmonary, Systemic 
4.8.3 Organizational Changes in a Pandemic Situation 

Module 5. Nuclear Medicine in Pediatrics 

5.1. Pediatric Nuclear Medicine 

5.1.1. Management of the Child in Nuclear Medicine: Information to Parents and/or Guardians, Preparation and Scheduling, Appropriate Environments 
5.1.2. Dose Optimization 
5.1.3. Sedation and Anaesthesia 
5.1.4. Physical Aspects in Pediatric Patients: Image Acquisition and Processing 

5.2. PET/PET-CT/PET-MRI in Pediatric and Young Adult Patients 

5.2.1. Protocol Optimization 
5.2.2. Indications  
5.2.3. Non-FDG Tracers 

5.3. Central Nervous System/LCR 

5.3.1. Brain Maturation Patterns 
5.3.2. Epilepsy and Vascular Disorders 
5.3.3. Brain Tumors 
5.3.4. Hydrocephalus and Cerebrospinal Fluid Fistula 

5.4. Endocrine 

5.4.1. Thyroid Pathology: Hypothyroidism, Hyperthyroidism, Thyroid Nodule 
5.4.2. Hyperinsulinism 

5.5. Cardiopulmonary 

5.5.1. Congenital Heart Disease: Shunt Right-Left, Shunt Left-Right 
5.5.2. Bronchopulmonary Pathology: Congenital and Acquired 

5.6. Gastrointestinal System 

5.6.1. Dynamic Esophagogastric Studies 
5.6.2. Gastroesophageal Reflux, Bronchopulmonary Aspiration 
5.6.3. Hepatobiliary Gammagraphy: Biliary Tract Atresia 
5.6.4. Intestinal Bleeding: Mekel's Diverticulum, Intestinal Duplication 

5.7. Nephrourology 

5.7.1. Hydronephrosis Assessment 
5.7.2. Renal Cortical Assessment: in Infections, Ectopy 
5.7.3. Vesicoureteral Reflux: Diagnosis and Monitoring 
5.7.4. Others: Renal Malformations, Renal Transplantation, Kidney Transplantation 

5.8. Osteoarticular System 

5.8.1. Benign Lesions in Pediatric Patients: Fractures, Tumors 
5.8.2. Avascular Necrosis: Perthes' Disease and Others 
5.8.3. Sympathetic - Reflex Dystrophy 
5.8.4. Low Back Pain 
5.8.5. Infection: Osteomyelitis, Spondylodiscitis 

5.9. Neuroblastoma  

5.9.1. Diagnostic Studies: Bone Scintigraphy, MIBG and other PET Radiotracers 
5.9.2. Radiometabolic Treatment: MIBG, 177Lu-DOTATATE 

5.10. Other Tumours 

5.10.1. Osteosarcoma: Diagnosis, Response Assessment and Monitoring 
5.10.2. Bone Tracers and 18F-FDG-PET/CT PET/CT Study 
5.10.3. Ewing's Disease: Diagnosis, Response Assessment and Monitoring 
5.10.4. Bone Tracers and 18F-FDG-PET/CT Study 
5.10.5. Lymphoma: 18F-FDG PET/CT in Diagnosis, Response Assessment, Monitoring 
5.10.6. Rhabdomyosarcoma and Soft Tissue Sarcomas: 18F-FDG PET/CT in Diagnosis, Response Assessment and Monitoring 

Module 6. Neuroendocrine Tumors 

6.1. Causes and Risk Factors 

6.1.1. Hereditary Syndromes 

6.2. Clinical presentation  

6.2.1. Signs 
6.2.2. Symptoms: Endocrine Syndromes 

6.3. Anatomopathological Diagnosis  

6.3.1. Degrees of Cellular Differentiation 
6.3.2. Classification 

6.4. Subtypes and Locations 

6.4.1. Extrapancreatic 
6.4.2. Pancreatic 

6.5. Staging  

6.5.1. Endoscopic Technique 
6.5.2. Imaging Techniques 
6.5.3. Echo, CT, MRI 

6.6. Molecular Techniques 

6.6.1. 111In, 99mTc, 8Ga-labeled Somatostatin Analogs 
6.6.2. Advantages and Disadvantages of Each of Them Best Choice Based on Availability 
6.6.3. 18F-FDG: Contributions to Patient Management 
6.6.4. Combined FDG-Somatostatin Analogues Studies 
6.6.5. Other Targets  

6.7. Treatment  

6.7.1. Treatments Available 
6.7.2. Radiometabolic Therapy: When and How? 

6.8. Assessment of Response to Treatment 

6.8.1. Clinical-Biochemistry 
6.8.2. Morphological 
6.8.3. Functional Criteria 

6.9. Monitoring  

6.9.1. Clinical-Biochemistry 
6.9.2. Image: Morphological and Functional Best Sequence 

6.10. Clinical Trials 

6.10.1. Therapy Sequencing 
6.10.2. Association: Combined Treatments 

Module 7. Radioguided Surgery 

7.1. Selective Biopsy of the Sentinel Ganglion (SBSG) 

7.1.1. Detection with Radiopharmaceutical and Combined Techniques 

7.1.1.1. Radiocolloids, Dyes 
7.1.1.2. BSGC Breast Cancer 

7.1.2. Initial Staging 
7.1.3. In Neoadjuvant  

7.2. BSGC Gynecologic Tumors 

7.2.1. Vulva 
7.2.2. Cervix  
7.2.3. Endometrium 
7.2.4. Ovaries 

7.3. BSGC Skin Cancer 

7.3.1. Melanoma 
7.3.2. Non-Melanoma 

7.4. BSGC Head and Neck Tumors 

7.4.1. Thyroid Cancer 
7.4.2. Oral Cavity 

7.5. BSGC Gastrointestinal Tumors 

7.5.1. Oesophageal Cancer 
7.5.2. Stomach Cancer 
7.5.3. Colorectal Carcinoma 

7.6. BSGC Urological Cancers 

7.6.1. Penis 
7.6.2. Prostate 

7.7. Combined Technique of BSGC and Radioguided Occult Lesion Localization (ROLL) 

7.7.1. Breast  
7.7.2. Other Locations 

7.8. ROLL 

7.8.1. Radiopharmaceuticals 99mTc, Seeds 125-I 
7.8.2. Indications: Tumor Pathology and Other Applications 

7.9. Radioguided Surgery in Primary Hyperparathyroidism 

7.9.1. Indications 
7.9.2. Protocols According to Radiopharmaceuticals 

Module 8. PET/CT- PET/MRI in Oncology Clinical Guidelines 

8.1. Nuclear Medicine in Different Tumors 

8.1.1. Staging and Prognosis 
8.1.2. Response to Treatment  
8.1.3. Monitoring and Diagnosis of Recurrence 

8.2. Lymphomas 

8.2.1. Hodgkin’s Lymphoma 
8.2.2. Diffuse Large B-cell Lymphoma 
8.2.3. Other Lymphomas 

8.3. Breast Cancer 

8.3.1. Initial Staging 
8.3.2. Response to Neoadjuvant 
8.3.3. Monitoring 

8.4. Gynecologic Tumors 

8.4.1. Vagina Cervix: Staging, Response to Treatment and Monitoring 
8.4.2. Endometrium: Staging, Response to Treatment and Monitoring 
8.4.3. Ovaries: Staging, Response to Treatment and Monitoring 

8.5. Lung Cancer 

8.5.1. Non-small Cell Lung Carcinoma 
8.5.2. Small Cell Lung Carcinoma 
8.5.3. Response Assessment: Radiotherapy, Immunotherapy 

8.6. Digestive System Tumors  

8.6.1. Esophago-Gastric  
8.6.2. Colorectal  
8.6.3. Pancreas 
8.6.4. Hepatobiliary: Hepatocarcinoma, Cholangiocarcinoma 

8.7. Sarcomas 

8.7.1. Bones 
8.7.2. Soft Parts 

8.8. Urogenitals  

8.8.1. Prostate 
8.8.2. Renal  
8.8.3. Bladder 
8.8.4. Testicle 

8.9. Endocrine 

8.9.1. Thyroid 
8.9.2. Adrenal Gland 

8.10. Radiotherapy Planning 

8.10.1. Acquisition of Exploration 
8.10.2. Volume Delimitation 

Module 9. Radioligand Targeted Therapy 

9.1. Theragnosis 

9.1.1. Clinical and Therapeutic Implications 

9.2. Thyroid 

9.2.1. Hyperthyroidism 
9.2.2. Differentiated Thyroid Carcinoma 
9.2.3. Goiter 

9.3. Neuroendocrine, Gastroenteropancreatic and Other Tumors: Radiolabeled Peptides 

9.3.1. Indications 
9.3.2. Administration 

9.4. Pheochromocytoma and Paragangliomas: 131I-MIBG 

9.4.1. Indications and Patient Selection 
9.4.2. Administration Protocols 
9.4.3. Results  

9.5. Bone Metastases  

9.5.1. Pathophysiology of Bone Metastases 
9.5.2. Basis of Metabolic Radiotherapy 
9.5.3. Radiopharmaceuticals Used: Indications and Results 

9.6. Selective Internal Radiation Therapy (SIRT): Labeled Microspheres  

9.6.1. Basis of Therapy with Radiolabeled Microspheres 
9.6.2. Available Devices: Differential Characteristics 
9.6.3. Calculation of the Activity to be Administered and Dosimetric Assessment according to the Device 
9.6.4. Hepatocarcinoma: Application and Results  
9.6.5. Liver Metastases: Application and Results in Colorectal Carcinoma, Neuroendocrine and Other Tumors 
9.6.6. Contributions of SIRT to Liver Surgery 
9.6.7. Potentially Resectable Patient 
9.6.8. Hepatic Lobe Hypertrophy 

9.7. Synoviorthesis  

9.7.1. Pathophysiological Basis of Treatment 
9.7.2. Radiopharmaceuticals Used 
9.7.3. Indications and Clinical Experience in Different Locations and Pathologies: Rheumatoid Arthritis, Other Arthritis, Vellonodular Synovitis 
9.7.4. Applications in Pediatrics: Hemophilic Patient 

9.8. Metastatic Prostate Cancer: 177Lu-PSMA  

9.8.1. Pathophysiological Bases 
9.8.2. Patient Selection 
9.8.3. Management Protocols and Results 

9.9. Lymphomas: Radioimmunotherapy 

9.9.1. Pathophysiological Bases 
9.9.2. Indications 
9.9.3. Administration Protocols 

9.10. Future  

9.10.1. Search for New Ligands and Radioisotopes 
9.10.2. Translational Research  
9.10.3. Research Lines 

Module 10. The Nuclear Medicine 

10.1. Physical Bases of Ionizing Radiations 

10.1.1. Ionizing Radiation and Radioactive Isotopes 
10.1.2. Types of Radiation 

10.2. Biological Effects of Ionizing Radiations 

10.2.1. Classification of Effects according to: Time of Occurrence 
10.2.2. Biological and Dose Dependent Effect 
10.2.3. Interaction of Ionizing Radiation with Matter 
10.2.4. Ionizing Radiation-Cell Interaction: Characteristics, Direct and Non-Direct Effects 
10.2.5. Radiosensitivity 
10.2.6. Adaptive Response 

10.3. Radiopharmaceuticals 

10.3.1. The Radiopharmaceutical 
10.3.2. Conventional Diagnostic Radiopharmaceuticals 
10.3.3. Radionuclide Generators 
10.3.4. Localization Mechanisms 
10.3.5. Positron Emission Tomography Radiopharmaceuticals 
10.3.6. Synthesis Scheme 
10.3.7. Metabolic Pathway Substrates 
10.3.8. Radiopharmaceuticals with Therapeutic Effect 

10.3.8.1. Characteristics that Must be Met 
10.3.8.2. Design and Approval 

10.4. Radiopharmacy 

10.4.1. Operation 
10.4.2. Quality Control  

10.5. Image Acquisition and Processing 

10.5.1. Planar Image 
10.5.2. Components 
10.5.3. Performance: Resolution and Sensitivity 
10.5.4. Acquisition Modes: Static, Dynamic, Synchronized 
10.5.5. Reconstruction 
10.5.6. Single Photon Tomography (SPECT) 
10.5.7. Acquisition 
10.5.8. Reconstruction 
10.5.9. Positron Emission Tomography (PET) 
10.5.10. Components 
10.5.11. Acquisition of Data 
10.5.12. Operating Parameters 

10.6. Quantification Techniques: Basis 

10.6.1. In Cardiology 
10.6.2. In Neurology 
10.6.3. Metabolic Parameters 
10.6.4. The Image of TC 

10.7. Image Generation 

10.7.1. Acquisition and Reconstruction Parameters 
10.7.2. Protocols and Contrast Media 
10.7.3. Head and Neck 
10.7.4. Thorax: Cardiology and Lung 
10.7.5. Abdomen: General, Liver, Renal 

10.8. The Image of RM 

10.8.1. Resonance Phenomenon 
10.8.2. Tissue Contrast: Sequence Knowledge 
10.8.3. Diffusion 
10.8.4. Paramagnetic Contrasts 

10.9. The Multimodality Image  

10.9.1. SPECT/TC 
10.9.2. PET/TC 
10.9.3. PET/RM 

10.10. Radioprotection 

10.10.1. The Radioprotection 
10.10.2. Special Situations: Pediatrics, Pregnancy and Lactation 
10.10.3. Dosimetry

These contents will make you a great expert in Nuclear Medicine”